Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 4/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 2/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21687820 | 0.97 | ATM (0.40) | KDM4EATML3MBTL1PTGER4METAP2 | |
| SCHEMBL21687667 | 0.97 | CYP19A1 (0.35) | KDM4EMETAP2TDP2CYP19A1RARG | |
| SCHEMBL21688216 | 0.93 | KDM4E (0.37) | KDM4EATML3MBTL1PTGER4METAP2 | |
| SCHEMBL21687748 | 0.91 | PTGER4 (0.36) | KDM4EATML3MBTL1PTGER4TDP2 | |
| SCHEMBL21687678 | 0.91 | KDM4E (0.37) | KDM4EATML3MBTL1PTGER4METAP2 | |
| SCHEMBL21687521 | 0.90 | KDM4E (0.35) | KDM4EATML3MBTL1PTGER4TDP2 | |
| SCHEMBL21688033 | 0.90 | TDP2 (0.35) | KDM4ETDP2CYP19A1RARGG6PD | |
| SCHEMBL21687525 | 0.89 | METAP2 (0.34) | KDM4EATML3MBTL1PTGER4METAP2 | |
| SCHEMBL21687863 | 0.89 | KDM4E (0.34) | KDM4EATML3MBTL1PTGER4METAP2 | |
| SCHEMBL21687513 | 0.89 | METAP2 (0.33) | KDM4EATML3MBTL1PTGER4METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-12-14 | — | — | US | disclosed |
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | CRY1, CCNL2, CCNE2 | KDM4E 2977/4885ATM 1151/4885L3MBTL1 1003/4885 |
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | CRY1, CCNL2, CCNE2 | KDM4E 2977/4885ATM 1151/4885L3MBTL1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.